

**Arecor Therapeutics plc**  
("Arecor", the "Company" or the "Group")

**Exercise of rollover options and Total Voting Rights**

**Cambridge, UK, 9 June 2023:** Arecor Therapeutics plc (AIM: AREC) the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that it has issued and allotted 7,471 new Ordinary Shares of 1 pence each in the share capital of the Company following an exercise of options on 8 June 2023 at an exercise price of 1 pence per Ordinary Share. The options exercised were part of the rollover of share options previously granted under the Arecor Limited EMI Share Option Plan 2018 ("Option Rollover"). Details of the Option Rollover are set out in the Company's Admission Document.

**Admission**

Following the above transactions, application has been made for the 7,471 new Ordinary Shares to be admitted to trading on AIM ("Admission") and dealings are expected to commence on, or around, 14 June 2023. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.

The total number of Ordinary Shares in issue following Admission will be 30,625,654. Accordingly, the figure of 30,625,654 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

**-ENDS-**

**For more information, please contact:**

**Arecor Therapeutics plc**

Dr Sarah Howell, Chief Executive Officer

[www.arecor.com](http://www.arecor.com)

Tel: +44 (0) 1223 426060

Email: [info@arecor.com](mailto:info@arecor.com)

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: [info@arecor.com](mailto:info@arecor.com)

Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Email: [mo.noonan@arecor.com](mailto:mo.noonan@arecor.com)

**Panmure Gordon (UK) Limited** (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

**Consilium Strategic Communications**

Chris Gardner, David Daley, Lindsey Neville

Tel: +44 (0) 20 3709 5700

Email: [arecor@consilium-comms.com](mailto:arecor@consilium-comms.com)

**Notes to Editors**

**About Arecor**

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, [www.arecor.com](http://www.arecor.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

